[HTML][HTML] Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood γδ T cells
Haematologica, 2010•ncbi.nlm.nih.gov
Background Vγ9Vδ2 T lymphocytes are regarded as promising mediators of cancer
immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly
within those of hematopoietic origin. However, Vγ9Vδ2 T-cell based lymphoma clinical trials
have suffered from the lack of biomarkers that can be used as prognostic of therapeutic
success.
immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly
within those of hematopoietic origin. However, Vγ9Vδ2 T-cell based lymphoma clinical trials
have suffered from the lack of biomarkers that can be used as prognostic of therapeutic
success.
Abstract
Background
Vγ9Vδ2 T lymphocytes are regarded as promising mediators of cancer immunotherapy due to their capacity to eliminate multiple experimental tumors, particularly within those of hematopoietic origin. However, Vγ9Vδ2 T-cell based lymphoma clinical trials have suffered from the lack of biomarkers that can be used as prognostic of therapeutic success.
ncbi.nlm.nih.gov